Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Amneal Gains Approval for Erythromycin Tablets USP

Amneal Pharmaceuticals LLC
Posted on: 14 Mar 18
Amneal Gains Approval for Erythromycin Tablets USP

PR Newswire

BRIDGEWATER, N.J., March 14, 2018

BRIDGEWATER, N.J., March 14, 2018 /PRNewswire/ -- Amneal Pharmaceuticals has received FDA approval for Erythromycin Tablets USP, 250 mg and 500 mg strengths.  The Amneal product is a therapeutic equivalent for the reference listed drug (RLD) Erythromycin Tablets from Arbor Pharmaceuticals and is the only other immediate release oral tablet available. 

"Amneal is committed to increasing access to affordable medications," said Amneal EVP-Commercial Operations Andy Boyer. "Erythromycin tablets are a great example of a product with limited availability where we can now provide patients and pharmacists with options."

Amneal's erythromycin tablets are sold in 100-count bottles and are now available to wholesalers, distributors and direct to the trade.

Annual U.S. sales of erythromycin tablets were $84 million, according to January 2018 IQVIA™ market data.

About Amneal

Amneal Pharmaceuticals LLC, a privately-held company headquartered in Bridgewater, New Jersey, is one of the largest and the fastest growing generics pharmaceutical manufacturers in the United States. Founded in 2002, Amneal now has more than 5,000 employees in North America, Asia and Europe, working together to bring high quality affordable medicines to patients worldwide. Amneal has significantly expanded its portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas.

Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. (NASDAQ: IPXL) announced on October 17, 2017 that they have entered into a definitive business combination agreement with the resulting combined company expected to create the 5th largest generics business (by gross revenue) in the United States. The transaction is expected to close in the first half of 2018.

For more information, visit

All trademarks listed in this release are property of their respective owners. 
Product photo is available upon request.



Andy Boyer

Executive Vice President, Commercial Operations


Business Development

Apurva Saraf

Vice President, Global Strategy & Corporate Development



Cheryl Lechok

Media Relations



View original content with multimedia:

SOURCE Amneal Pharmaceuticals LLC

PR Newswire

Last updated on: 14/03/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.